HomeAI · summaries
Storia in 2 fonti
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
The startup is developing a medicine that works differently than available treatments for thyroid eye disease and could benefit people with a related condition, too.
- ·
endpoints.news
Ethyreal lands $101M to treat both Graves' and thyroid eye disease
Ethyreal Bio emerges from stealth with $101M to develop ETHY-001, a TSHR-targeting antibody for Graves' disease and thyroid eye disease, with a clinic entry planned by end of 2026.